HIND
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Vyome was granted a Chinese patent strengthening its immuno-inflammation portfolioJul 1, 2026
- Vyome met all VT-1953 Phase 3 funding requirements for initial resultsFeb 2, 2026
- Vyome reports positive final Phase 2 results for VT-1953 and plans pivotal study for FDA approvalDec 8, 2025
- Vyome presents strong data showing topical VT-1908 is an effective treatment for uveitis, opening up a $3B addressable market opportunitySep 17, 2025
- Vyome Holdings announces positive interim data from Phase 2 study of VT-1953 in malignant fungating wounds and provides update on market opportunitySep 4, 2025